We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Specific Biomarker Assessed for Cartilage Degradation

By LabMedica International staff writers
Posted on 21 Jun 2017
Print article
Image: An illustration of Coll2-1, a marker specific of type II collagen degradation in osteoarthritis (Photo courtesy of Artialis).
Image: An illustration of Coll2-1, a marker specific of type II collagen degradation in osteoarthritis (Photo courtesy of Artialis).
Osteoarthritis (OA) is one of the most common forms of musculoskeletal disorders and one of the major causes of pain and disability in the adult population. Viscosupplementation is a symptomatic treatment of the knee osteoarthritis based on the intra-articular injection of hyaluronic acid (IAHA).

Several soluble biomarkers have been identified as potential candidates to predict or monitor the efficacy of intervention in OA. Type II collagen derivatives have been extensively investigated and Coll2-1, a degradation product of type II collagen, has been found in high concentrations in the synovial fluid of human patients with OA compared with healthy controls.

Scientists at the University Hospital of Liège (Liège, Belgium) and their French colleagues included 81 patients with symptomatic knee osteoarthritis in a randomized placebo controlled trial testing a reticulated hyaluronic acid (HA) with mannitol versus saline. The primary outcome was the percentage of patients with a reduction of at least 10 nmol/L of serum Coll2-1 between baseline and day 90 (D90, three months after injection).

Blood samples were collected and Coll2-1 was determined in patients’ sera using enzyme-linked immunosorbent assay (ELISA) kits. This assay is a competitive immunoassay utilizing a synthetic peptide pre-coated onto the ELISA plate for the quantification of the corresponding antigen in serum samples. The antibody-antigen complex is detected by a chromogenic reaction with 3,3’,5,5’-tetramethylbenzidine (TMB). The reaction is stopped by adding acid to give a colorimetric endpoint that is subsequently determined spectrophotometrically. The limits of quantification for the assay ranged from 31.25 nM to 2,000 nM.

The scientists found that a significant effect of the injection was revealed by the sensitivity analysis of the decrease in cartilage marker. In the intention-to-treat population, the percentage of patients showing a decrease in the levels of serum Coll2-1 between inclusion and D90 showed was higher in HA (56.8%) than in placebo group (28.6%). The same significant difference was observed between groups in the per protocol population: 57.1% versus 29.0%; corresponding to all patients having received the intra-articular injection (IA), being evaluated for the primary outcome on D-10 and D90, and with no major defined deviation.

The authors concluded that an IA injection of reticulated HA with mannitol in knee osteoarthritis patients can reduce the serum levels of Coll2-1, a marker specific of type II collagen degradation. This finding suggests that the specific injection may have a beneficial effect on cartilage degradation and that Coll2-1 could be used for the assessment of a single intra-articular treatment in clinical trials. The study was published on May 26, 2017, in the journal BMC Musculoskeletal Disorders.

Related Links:
University Hospital of Liège

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.